STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Phase 3positivePositive

AI Analysis

Summary

Vaxcyte announced positive Phase 3 trial results for its experimental pneumococcal vaccine, meeting primary endpoints and positioning itself to compete with Pfizer and Merck in the vaccine market.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Hit primary endpoints

Importance:7/10

Sentiment:

0.75

vaccinepneumococcalPhase 3clinical trialcompetitive landscape

Related Companies

$PFE $MRK

Read the original article

Published by STAT News on October 5, 2026 12:19 PM

Read Original